KEA1-97 |
|
カタログ番号GC63031
|
KEA1-97 は、選択的なチオレドキシン-カスパーゼ 3 相互作用阻害剤です (IC50=10 μM)。 KEA1-97 は、チオレドキシンとカスパーゼ 3 との相互作用を妨害し、カスパーゼを活性化し、チオレドキシン活性に影響を与えることなくアポトーシスを誘導します。
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 2138882-71-8
Sample solution is provided at 25 µL, 10mM.
KEA1-97 is a selective Thioredoxin-caspase 3 interaction disruptor (IC50=10 μM). KEA1-97 disrupts the interaction of thioredoxin with caspase 3, activates caspases, and induces apoptosis without affecting thioredoxin activity[1].
KEA1-97 (100 μM; 231MFP cells) impaires thioredoxin pulldown of caspase 3[1].KEA1-97 (10 μM; 48 hours; 231MFP cells) impaires 231MFP serum-free cell proliferation[1].KEA1-97 (10 μM; 0~12 hours; 231MFP cells) activates caspase 3/7 and induces apoptotic cell death[1].KEA1-97 (231MFP cells) resistants to survival and proliferation impairments[1].
KEA1-97 (5 mg/kg; i.p.; 50 days) attenuates tumor xenograft growth[1].
[1]. Anderson KE, et al. Chemoproteomics-Enabled Covalent Ligand Screening Reveals a Thioredoxin-Caspase 3 Interaction Disruptor That Impairs Breast Cancer Pathogenicity. ACS Chem Biol. 2017;12(10):2522-2528.
| Cas No. | 2138882-71-8 | SDF | |
| Formula | C15H9Cl2FN4 | M.Wt | 335.16 |
| 溶解度 | DMSO : 100 mg/mL (298.36 mM; Need ultrasonic) | Storage | 4°C, protect from light |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 2.9836 mL | 14.9182 mL | 29.8365 mL |
| 5 mM | 596.7 μL | 2.9836 mL | 5.9673 mL |
| 10 mM | 298.4 μL | 1.4918 mL | 2.9836 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >99.50% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 27 reference(s) in Google Scholar.)















